Sebastian Schneeweiss, MD, ScD, is Professor of Medicine and Epidemiology at Harvard Medical School and Vice Chief of the Division of Pharmacoepidemiology and Pharmacoeconomics of the Department of Medicine, Brigham and Women’s Hospital, a world-leading research and training center.
His research is funded by multiple NIH, PCORI, and FDA grants and focuses on the comparative effectiveness and safety of biopharmaceuticals. He has developed analytic methods to improve the scientific validity of epidemiologic analyses using complex longitudinal healthcare databases particularly for newly marketed medical products. Applying such methods transparently and in rapid cycles for sequential medication effectiveness monitoring is the overarching theme of his research. His work is published in >300 articles, many of them in high-ranking journals. He is Aetion Inc.’s Science Lead were he develops a worldwide network of rapid-cycle analytics platforms that produces evidence fit for decision making in healthcare.
Dr. Schneeweiss is Director of the Harvard-Brigham Drug Safety Research Center funded by FDA/CDER and Co-Chair of the Methods Core of the FDA Sentinel program. He is voting consultant to the FDA Drug Safety and Risk Management Advisory Committee and was inaugural member of the Methods Committee of the Patient Centered Outcomes Research Institute. He was President of the International Society for Pharmacoepidemiology, inaugural member of the PCORI Methods Committee and is Fellow of the American College of Epidemiology, the American College of Clinical Pharmacology, and the International Society for Pharmacoepidemiology.
At Harvard he teaches courses on Database Analytics for Pharmacoepidemiology and on Effectiveness Research in Longitudinal Healthcare Databases among others.
He received his medical training at the Ludwig-Maximilians University of Munich and his doctoral degree in pharmacoepidemiology from Harvard.